What is LevitasBio?
LevitasBio is at the forefront of developing innovative solutions for sample preparation and characterization in the life sciences sector. Leveraging proprietary levitation technology, the company offers advanced tools such as the LeviCell systems for cell enrichment, LeviPrep for tissue processing, and LeviMetrics for detailed sample analysis. These offerings are designed to enhance research outcomes for complex biological samples, catering to academic institutions and research facilities. LevitasBio's technology aims to improve sample viability, increase throughput, and reduce costs, making it an indispensable asset for modern scientific research, particularly in areas like single-cell genomics, cancer profiling, and 3D culture modeling.
How much funding has LevitasBio raised?
LevitasBio has raised a total of $61M across 3 funding rounds:
Series A
$8M
Series B
$18M
Series C
$35M
Series A (2017): $8M with participation from Decheng Capital
Series B (2021): $18M led by Decheng Capital and Thalys Medical
Series C (2022): $35M supported by Pavilion Capital, Novalis LifeSciences, and Decheng Capital
Key Investors in LevitasBio
Pavilion Capital
Pavilion Capital Partners is a growth-oriented private equity investor focused on fast-growing companies in the United States and Asia, particularly in industries experiencing high growth due to globalization, technology, or demographic trends. They provide capital and strategic support to assist in strategic initiatives, mergers and acquisitions, and eventual liquidity.
Novalis LifeSciences
Novalis LifeSciences LLC is a boutique investment and advisory firm founded in 2017, specializing in life science tools, diagnostics, and biopharma therapeutics. They provide direct investments and business advisory services, managing $500M in assets across three funds.
Decheng Capital
Decheng Capital is a global investment firm established in 2012, specializing in providing capital and strategic support to early-stage life science companies and growth stage healthcare companies. With over $2.1 billion in capital, the firm aims to build legendary companies by leveraging revolutionary technologies and strong market presence.
What's next for LevitasBio?
The recent major strategic investment signals a strong vote of confidence in LevitasBio's technological innovation and market potential. This capital infusion is expected to accelerate the company's growth trajectory, enabling further development of its product pipeline and expansion into new research applications. LevitasBio is poised to solidify its position as a leader in advanced biological sample tools, driving scientific discovery and enabling breakthroughs in critical areas of life science research.
See full LevitasBio company page
